title: Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis.
abstract: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic, progressive, systemic inflammatory rheumatic diseases that lead to serious disability. The objective of this study was to investigate the demographic and clinical characteristics of the patients with RA and AS who were treated in tertiary hospitals in Turkey and to analyze their current medical management. A total of 562 RA and 216 AS patients were evaluated. The mean age of RA patients was 52.1 +/- 12.6 years. The female to male ratio was 3.7:1. Of the RA patients, 72.2% had positive rheumatoid factor (RF), 62.9% had high C-reactive protein, and 75.2% had radiological erosion. The ratio of patients with Disease Activity Score (DAS) 28 >3.2 was 73.9% and of those with Health Assessment Questionnaire (HAQ) > or =1.5 was 20.9%. There was a statistically significant increase in RF positivity and HAQ scores in the group with higher DAS 28 score. Frequency of extraarticular manifestations was 22.4%. The ratio of the patients receiving disease modifying antirheumatic drugs (DMARD) was 93.1%, and 6.9% of the patients were using anti-tumor necrosis factor (TNF) blocking agents. In AS, the mean age of the patients was 38.1 +/- 10.6, and the female to male ratio was 1:2.5. The time elapsed between the first symptom and diagnosis was 4.3 years. The ratio of peripheral joint involvement was 29.4%. Major histocompatibility complex, class I, B 27 was investigated in 31.1% of patients and the rate of positivity was 91%. In 52.4% of the patients, Bath AS Disease Activity Index (BASDAI) was > or =4. The erythrocyte sedimentation rate, Bath AS Functional Index, and peripheral involvement were significantly higher in the group with BASDAI > or =4. Frequency of extraarticular involvement was 21.2% in AS patients. In the treatment schedule, 77.5% of AS patients were receiving sulphasalazine, 15% methotrexate, and 9.9% anti-TNF agents. Despite widespread use of DMARD, we observed high disease activity in more than half of the RA and AS patients. These results may be due to relatively insufficient usage of anti-TNF agents in our patients and therefore these results mostly reflect the traditional treatments. In conclusion, analysis of disease characteristics will inform us about the disease severity and activity in RA and AS patients and could help in selecting candidate patients for biological treatments.
authors: Physical Medicine and Rehabilitation (PMR) Department, Ankara Numune Training and Research Hospital, Mürsel Uluç Ankara, Turkey. haticebodur@gmail.com
authors: H
authors: H
authors: Bodur
authors: S
authors: S
authors: Ataman
authors: L
authors: L
authors: Akbulut
authors: D
authors: D
authors: Evcik
authors: V
authors: V
authors: Kavuncu
authors: T
authors: T
authors: Kaya
authors: R
authors: R
authors: Günaydin
authors: B
authors: B
authors: Kuran
authors: N
authors: N
authors: Kotevoğlu
authors: A
authors: A
authors: Bal
authors: E
authors: E
authors: Aydoğ
authors: Z
authors: Z
authors: Altay
authors: H
authors: H
authors: Uğurlu
authors: H
authors: H
authors: Kocabaş
authors: N
authors: N
authors: Olmez
authors: P
authors: P
authors: Yazgan
authors: S
authors: S
authors: Gürsoy
authors: E
authors: E
authors: Madenci
authors: S
authors: S
authors: Ozel
authors: S U
authors: SU
authors: Delialioğlu
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011859:Radiography; D012217:Rheumatoid Factor / Q000032:analysis; D013167:Spondylitis, Ankylosing / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D012460:Sulfasalazine / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D012460:Sulfasalazine; D002097:C-Reactive Protein; D012217:Rheumatoid Factor; D008727:Methotrexate